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The morphology of the tumor and the anatomic extent of the disease are important factors
influencing treatment selection and ultimately survival for patients with lung cancer. The
American Joint Committee TNM system provides a method for consistent reproducible
description of the primary tumor (T), the status of the regional lymph nodes (N), and the
presence or absence of distant metastasis (M). The TNM subsets thus classified can be grouped
into three "stages" of disease such that the survival expectations for patients in each stage and
cell type are similar. This classification of patients with respect to estimates oftheir prognosis is
essential for valid comparisons of treatment modalities and meaningful communication of end
results information.
Clinical characteristics which influence survival are reflected in the staging recommendations.
The size of the lesion, the proximal margination, and the presence or absence of other
pulmonary complications are features which distinguish the T classification as T1, T2, or T3.
The presence or absence of lymph node involvement has an important bearing on survival
expectations. Advancing from no nodal involvement, NO, to involvement of the peribronchial
and hilar nodes, Nl, and then to the mediastinal nodes, N2, causes progressive erosion in
survival expectations. The tumor morphology and specific nodes that are involved are
important components of this relationship. The presence of distant metastasis, Ml, is synony-
mous with an extremely poor prognosis. Using these prognostic elements, the TNM subsets are
combined into three stages ofdisease so that patients in each group will have a generally similar
life expectancy, the survival for patients with stage I disease beingsignificantly greater than that
for patients with stage 11 disease which is significantly greater than survival for patients with
stage III disease.
Improvements in the outcome for lung cancer patients depend upon the depth and scope of
our scientific understandings and our ability to communicate our observations to one another.
Measures of response to treatment can be translated into therapeutic practice only if uniform
evaluators are used. Accordingly, a reproducible valid system for staging of lung cancer is
recommended.
Advances in the diagnosis and therapy of lung cancer have related largely to
application of a multimodality treatment concept and to refinements in the treatment
selection process. Accurate, reproducible classification of histology and anatomic
extent of disease is fundamental to the rational application of these elements of
management.
By means ofthese classifications, we determine the nature ofthe tumor, describe its
biologic behavior, and assess the therapeutic options. The results of different
modalities of treatment can only be meaningful if they are based on a system of
uniform evaluators. For many years pathologists have directed their efforts toward
providing consistent criteria for histologic classification of lung cancer that mini-
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mized interobserver variability. Classification of disease extent using the TNM
system makes possible a common language for describing the total tumor burden in a
given patient at any specific point in the course ofthe disease. Accordingly, a clinical
stage, surgical evaluative stage, a postsurgical treatment-pathologic stage, retreat-
ment stage, and autopsy stage may all be applicable. Using this scheme and the
histologic information, a quantitative estimate of a patient's prognosis can be made.
Furthermore, the anatomic extent of disease expressed in terms of the primary
tumor, the regional lymph nodes, and distant metastasis serves as a valuable aid in
treatment planning.
The definitions for the TNM factors and stage grouping rules shown in Tables I
and 2 were developed by the Task Force on the Lung of the American Joint
Committee for Cancer Staging and End Results Reporting [1]. These recommenda-
tions were based on the analysis of survival patterns in a large series of patients with
primary lung cancer treated according to conventional or standard modalities.
The survival studies showed that a specific survival pattern for each major
histologic grouping, regardless of any other tumor, host, or therapeutic influence,
exists, and three significantly different survival patterns were evident according to
TABLE 1
TNM Classification
Primary Tumor (T)
TX Tumor proven by the presence of malignant cells in bronchopulmonary secretions but not
visualized roentgenographically or bronchoscopically, or any tumor that cannot be assessed
as in a retreatment staging.
TO No evidence of primary tumor.
TIS Carcinoma in situ.
Tl A tumor that is 3.0 cm or less in greatest diameter, surrounded by lung or visceral pleura, and
without evidence of invasion proximal to a lobar bronchus at bronchoscopy.
T2 A tumor more than 3.0 cm in greatest diameter, or a tumor ofany size that either invades the
visceral pleura or has associated atelectasis or obstructive pneumonitis extending to the hilar
region. At bronchoscopy, the proximal extent ofdemonstrable tumor must be within a lobar
bronchus or at least 2.0 cm distal to thecarina. Anyassociated atelectasis orobstructive pneu-
monitis must involve less than an entire lung, and there must be no pleural effusion.
T3 A tumor ofany size with direct extension into an adjacent structure such as the parietal pleura
or chest wall, the diaphragm, or the mediastinum and its contents; or a tumor demonstrable
bronchoscopically to involve a main bronchus less than 2.0 cm distal to the carina; or any
tumor associated with atelectasis or obstructive pneumonitis ofan entire lung or pleural effu-
sion.
Nodal Involvement (N)
NO No demonstrable metastasis to regional lymph nodes.
NI Metastasis to lymph nodes in the peribronchial or the ipsilateral hilar region, or both, in-
cluding direct extension.
N2 Metastasis to lymph nodes in the mediastinum.
Distant Metastasis (M)
MX Not assessed.
MO No (known) distant metastasis.
MI Distant metastasis present. Specify
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TABLE 2
Stage Grouping
Occult Carcinoma
TX NO MO
An occult carcinoma with bronchopulmonary secretions containing malignant cells but without other
evidence of the primary tumor or evidence of metastasis to the regional lymph nodes or distant metas-
tasis.
Stage I
TIS NO MO
Carcinoma in Situ
Ti NO MO
Ti NI MO
T2 NO MO
A tumor that can be classified Ti without any metastasis or with metastasis to the lymph nodes in the
peribronchial and/or ipsilateral hilar region only, or a tumor that can be classified T2 without any me-
tastasis to nodes or distant metastasis.
NOTE: TX Ni MO and TO NI MO are also theoretically possible, but such a clinical diagnosis
would be difficult if not impossible to make. If such a diagnosis is made, it would be in-
cluded in stage I.
Stage II
T2 Ni MO
A tumor classified as T2 with metastasis to the lymph nodes in the peribronchial and/or ipsilateral hilar
region only.
Stage III -
T3 with any N or M
N2 with any T or M
MI with any T or N
Any tumor more extensive than T2, or any tumor with metastasis to the lymph nodes in themediastinum,
or any tumor with distant metastasis.
measures ofdisease extent for patients with squamous cell, large cell, and adenocarci-
noma [2]. The necessity of reporting end results by cell type was clearly shown. No
parameters could be identified that affected the survival in patients with undifferen-
tiated small cell carcinoma and it was originally thought not to be worthwhile to
apply the staging system to them. Recent improvements in the treatment of patients
with small cell carcinoma with multidrug chemotherapy and multimodality treatment
have resulted in an increase of survival rate, especially in those with limited extent of
disease, and, therefore, it is now advisable to apply the TNM classification and stage
grouping to patients with this cell type. End results should be reported separatelyfor
the major histologic groupings or at least according to small cell and non-small cell
subsets.
STAGE GROUPING IN CARCINOMA OF THE LUNG
The "T" component describes the primary tumor and numerical descriptors, T1,
T2, and T3, reflect the survival dynamics, which are related to tumor size and
location, extent of proximal margination, and complications such as atelectasis,
obstructive pneumonitis, and pleural effusion. The "N" component describes the
regional lymph nodes and the survival dynamics, reflected by numeric descriptors,
NO, N1, and N2, are related to the absence of or to the presence and extent of such
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involvement. The "M" component describes distant metastasis and survival is related
to the presence or absence of such metastasis, MO or M1. The TNM subsets thus
classified are combined into three stages of disease, the patients in each stage having
relatively similar expectations for survival.
STAGE I DISEASE
The different common presentations of Stage I disease are shown in Fig. 1. In
patients with this classification all ofthe tumor and its manifestations are confined to
the lung of origin and all of the disease is considered completely resectable. Stage I
disease includes tumors that are less than 3 cm in greatest diameter with or without
peribronchial or hilar lymph node extension or metastasis. In the figure, a typical
"coin" lesion is shown in the periphery of the left upper lobe. The anticipated
survival for T1 NO MO patients is now sufficiently high that they are currently being
excluded from some national clinical trials of adjuvant treatment, since the value of
any adjuvant modalitywould be extremely hard to evaluate unless the treatment were
nearly 100 percent effective. Shown in the middle drawing, in the left upper lobe is a
similarly small lesion with metastasis to the peribronchial and hilar lymph nodes, Tl
N1 disease. Stage I disease includes larger tumors or those ofany sizethat invade the
visceral pleura, involve the main stem bronchus, or have associated atelectasis or
obstructive pneumonitis extending to the hilar region, but which have no evidence of
metastasis or direct extension to any lymph nodes, T2 NO disease, as illustrated in the
lower figure.
TI NO MO DISEASE
Figure 2 illustrates the typical roentgenographic appearance ofT1 NO MO disease
in a 60-year-old female patient who was a non-smoker. This lesion was found on
routine follow-up X-ray 14 years postdefinitive treatment for squamous cell carci-
noma of the cervix. The lesion was, however, considered to be a primary broncho-
genic carcinoma. Sputum cytology was negative, as was the distal metastatic screen.
Bronchoscopy revealed no endobronchial lesions and the findings at surgery con-
firmed the clinical stage assignment. Pathological report ofthewedge resection ofthe
right upper lobe ofthe lung was reported as bronchogenic squamous carcinoma and
direct transition from bronchiolar respiratory mucosa with tumor was identified,
substantiating lung origin. Hilar and mediastinal lymph node biopsies were negative.
STAGE II DISEASE
Stage II disease consists ofjust one subset, illustrated in Fig. 3, that is, T2 lesions
having involvement of the peribronchial and/or hilar nodes either through direct
extension or metastasis. The disease is technically completely resectable, but survival
expectations for non-small cell patients with Stage II disease vary according to
histologic classification. In squamous cell carcinoma, involvement of the regional
lymphatic structures does not carry as heavy a burden ofmortality as in the other cell
types. Involvement ofLthe hilar nodes in the presence of a tumor larger than 3 cm
causes a marked drop in survival expectations in patients with adenocarcinoma.
Shown in Fig. 3 are two examples of Stage II disease. In the left upper lobe, a tumor
invading the visceral pleura with metastasis to the hilar nodes only is shown. In the
right upper lobe, a tumor of the right upper lobe bronchus with obstructive
pneumonitis and metastasis to the hilar lymph nodes is shown.
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FIG. 1. Stage I Disease. From: Ameri-
can Joint Committee for Cancer Staging
and End Results Reporting: Staging of
Lung Cancer 1979. Chicago, IL. T2NOMO
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FIG. 2. Roentgenographic Appearance:
TI NO MO-Stage I Disease.
T2 NI DISEASE
This patient, whose X-ray is shown in Fig. 4, is a 71-year-old male whose disease
was discovered when he sought emergency medical attention for trauma to the chest
from a fall. A routine chest X-ray revealed a left ninth rib fracture and a left upper
lung mass. Figure 4 is our initial examination, showing a mass lesion in the posterior
segment of the left upper lobe with questionable hilar adenopathy. A calcified
granuloma was noted in the left lower lobe. At bronchoscopy, no abnormalities were
visualized within the tracheobronchial tree. Bronchial washings as well as cytological
examination of multiple sputum samples were negative. Screen for distal metastasis
was negative and no disease was found in the mediastinal lymph nodes at medias-
tinoscopy. A clinical state assignment of T2 NI MO-Stage II disease was made. The
patient underwent left upper lobectomy and pathological examination ofthe resected
specimen confirmed the extent of diseasewhich was reported as poorlydifferentiated
adenocarcinoma of the left upper lobe with metastasis to hilar and intrapulmonary
lymph nodes. No disease was found in the mediastinal lymph nodes removed at the
time ofsurgery. Our earlier studies ofend results accordingto postsurgical treatment-
pathologic stage showed that 18 percent of patients with this level of disease with
adenocarcinoma may be expected to achieve long-term survival following resection.
Accordingly, this patient was considered a candidateforsurgical adjuvant treatment,
and was subsequently randomized to a regimen involving multidrug chemotherapy,
designed for patients with this level of disease extent.
STAGE III DISEASE-OPERABLE
Patients with Stage III disease include those with tumors more extensive than T2
or any tumor with metastasis to the lymph nodes in the mediastinum or any tumor
with distant metastasis. Survival expectations for these Stage III patients overall are
very dismal. However, they can be dichotomized into inoperable and operable
groups. A less discouraging outcome may be anticipated for selected subsets ofStage
I11-MO patients having limited disease in which complete resection of all known
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tumor is technically feasible and is biologically rational. This latter admonition is
derived from observations of our own experience, and the work of others, that
patients with adenocarcinoma that has metastasized to the mediastinal lymph nodes
have an extremely poor prognosis [3]. Therefore, in terms of conventional single
modality treatment, patients of this histologic classification with N2 disease would
not be considered in the operable Stage III group. In contrast, a survival better than
what might be achieved with any other single modality may be anticipated for Stage
III-N2 MO patients with squamous cell or undifferentiated large cell carcinoma[3].
Two examples of this level of disease extent are shown in Fig. 5. In the upper
drawing, T2 tumor involving the hilar and tracheobronchial lymph nodes is shown.
One subset of Stage III-N2 disease that can be mistaken clinically for Stage I or
Stage II disease is shown in the lower figure, TI N2 disease, a small tumor with
metastasis to the hilum and mediastinal lymph nodes. An additional group of
operable Stage III patients are patients withT3 NO MO disease in which there is direct
extension of a peripheral primary tumor to the intercostal muscle and ribs. These are
T2N1MO
T2N1 MO
FIG. 3. Stage II Disease. Adapted
from: American Joint Committee for Can-
cer Staging and End Results Reporting:
Staging of LungCancer 1979. Chicago, IL.
167CLIFTON F. MOUNTAIN
FIG. 4. Roentgenographic Appearance:
£ T2 NI-Stage II Disease.
locally invasive lung tumors without evidence of regional or disseminated disease.
Pulmonary resection, usually lobectomy with en bloc resection, is undertaken with
marlex prosthetic repair or omental or musculocutaneous graft if necessary (Fig. 6).
Figure 7 is our initial examination of a patient determined clinically to have Stage
III-T2 N2 operable disease. He consulted his own physician for treatment of an
upper respiratory infection accompanied by low-grade fever and cough.
Our examination showed a large mass, in the left lower lobe with some associated
atelectasis or pneumonitis. The mass was judged clinically to be about 5 x 7 cm and
tomograms were confirmatory. Distal metastasis screen was negative. Bronchoscopic
examination showed tumor in the left lower lobe. At mediastinoscopy, right
paratracheal, left paratracheal, and tracheobronchial nodes were negative; however,
ipsilateral subcarinal lymph node biopsy was reported as containing metastatic
squamous cell carcinoma. The findings at surgery confirmed the clinical stage
assignment ofT2 N2 Stage I disease. Two of 15 hilar and two of 13 mediastinal nodes
were positive in the resected specimen.
STAGE III-INOPERABLE DISEASE
Unfortunately, the largest proportion of patients fall into this category at the time
of diagnosis. T2 N2 disease in which the high or proximal paratracheal or contra-
lateral paratracheal lymph nodes are involved are clinically excluded as surgical
candidates at mediastinoscopy. Tumors demonstrated at bronchoscopy to be less
than 2 cm from the carina, even if no positive lymph nodes are identified, are
classified as T3 and are generally unresectable. Those patients with T3 tumors
directly invading the aorta, main pulmonary artery or veins, recurrent or phrenic
nerves are likewise not surgical candidates. Another condition contributing to a
Stage III-T3 disease classification and placing patients in the inoperable group is
the presence of pleural effusion, which is clinically determined to relate to the
malignant process. In this regard, we noted that there was very little difference in
survival in those patients with pleural effusion that contained malignant cells and
those in whom no positive cells were identified.
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FIG. 5. Stage III Disease-Operable.
From: American Joint Committee for Can-
Ti N2MO cer Staging and End Results Reporting:
Staging of Lung Cancer 1979. Chicago, IL.
DISTANT METASTATIC SITES
The presence of distant metastasis outside the ipsilateral hemithorax and the
mediastinum, regardless of the T or N value, is indicative of Stage III disease and is
classified M1. Except in anecdotal cases, this usually is synonymous with a fatal
outcome.
The TNM system can be applied to most patients with lung cancer with certainty
and the appropriate stage designated with consistency. One group of 15 patients was
staged independently by 26 physicians and research assistants with more than 90
percent consistency in the TNM designations and stage assignment [4].
A system of classification which takes into account all variables influencing
survival would be hopelessly complex and unmanageable. The number of combina-
tions and permutations of all known or suspected variables is almost infinite. Even
large series of cases would be stratified to such an extent that very few patients would
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FIG. 6. Stage III Disease-Operable.
From: American Joint Committee for Can-
T3NOMO cer Staging and End Results Reporting: Staging of Lung Cancer 1979. Chicago, IL.
be classified in any one described subset ofthe total population. Furthermore, it must
be remembered that no two patients are completely similar nor can their characteris-
tics be completely described. In practice, we can only group together patients who are
generally alike. This is done byabstracting certain common features and disregarding
or omitting other aspects that are dissimilar.
The following suggestions are made as conventions which may be followed in the
interest of consistency.
SUGGESTIONS FOR APPLICATION OF THE
LUNG CANCER STAGING SYSTEM
The following suggestions for application ofthe LungCancer Staging System have
been published by the American Joint Committee, Task Force on the Lung, in the
recent fascicle, Staging of Lung Cancer, 1979.
TO is to be used when there is no demonstrable evidence of the primary tumor in
the lung but there is evidence of metastatic cancer in a lymph node or elsewhere
justifying a N1 or N2 or M1 designation, and it is concluded clinically that the
primiary is in the lung. TO may also be used in the Retreatment Staging of a patient
who had resection of his cancer and has proof of recurrence in the regional lymph
nodes or a distant metastasis without evidence of recurrence in the lung.
TX is used when a patient has a positive sputum for malignant cells but a negative
roentgenogram of the chest and a negative bronchoscopic examination. Such a
designation is usually temporary as in most cases the source of the positive sputum
can be localized and an appropriate T designation can be assigned. A clinical stage
assignment of TX NO MO could be made. TX may also be used in the Retreatment
Staging when it is impossible to evaluate the extent of residual primary tumor after
radiotherapy and the development of radiation pneumonitis and fibrosis in the field
of radiotherapy.
T2 is used when there is direct extension into the visceral pleura, but T3 is used if
the lesion directly invades the parietal pleura. Any ipsilateral discontinuous lesion or
lesions in or on the visceral or parietal pleura should be designated T3. However, a
discontinuous lesion outside the parietal pleura in the chest wall ordiaphragm should
be designated Ml. In contrast, a similar lesion in the mediastinum is most likely a
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lymph node that has been completely replaced by cancer cells and should be
designated N2.
Ipsilateral multiple primary tumors of the same cell type or unknown cell type
should be classified T2 unless there is other evidence of T3 disease.
Clinical classification of hilar masses may be difficult. If the hilar mass can be
separated from the mediastinum, hilar tomograms or computerized axial tomogra-
phy (CAT) may indicate whether the mass is the primary tumor or metastatic disease
in the hilar lymph nodes and the appropriate T and N designation assigned to the
patient. If the hilar mass cannot be separated from the mediastinum, especially if
there is a broad base of the lesion against the mediastinum, direct extension into the
mediastinum is probable and the lesion should be designated T3. Vocal cord
paralysis, superior vena caval obstruction, and compression of the trachea or the
esophagus are usually related to metastases to the mediastinal lymph nodes and, if
not proven otherwise, should be classified N2.
The MI designation should be used only when there is reasonable proof of
metastatic cancer, not when it is only possible. For example, elevated serum alkaline
phosphatase without other evidence of metastatic cancer in liver or bone would not
justify the designation Ml.
In all cases, the designation of the greatest extent of disease that is applicable for a
given patient should be used, but only when there is reasonable evidence of that
extent of disease. It is recognized that a number ofother factors beyond morphology
and anatomic extent of disease are important in the classification of lung cancer and
these are recognized and accounted for in the AJC recommendations, as follows:
First, the host performance status, (H), which is correlated with activity ofdisease
and prognosis, should be recorded before first treatment and at each subsequent
examination of the patient. Over a decade ago, Feinstein described the importance of
comorbidity as an index of tumor aggressiveness and growth rate [5]. The physical
state or performance status is designated H and takes into consideration all co-
factors. The values, which are equivalent to the Zubrod and Karnofsky scales, are as
FIG. 7. Roentgenographic Appearance
(Lateral View): Stage Ill-T2 N2 MO Dis-
ease.
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follows: HO is equivalent to normal activity; H1 represents symptomatic and
ambulatory status-patient is able to care for himself; H2 includes patients ambula-
tory more than 50 percent of the time, occasionally needing assistance; H3 includes
those patients ambulatory 50 percent or less ofthe time, nursing care needed, and H4
indicates a bedridden condition-the patient may need hospitalization.
Second, when the cancer is treated by definitive surgical procedures, residual
cancer, designated R, is recorded if any such disease is present. RO signifies no
residual tumor, R1, microscopic residual tumor, and R2, macroscopic residual
turmor.
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